Tag: hsCRP
-
Novo Nordisk Halts Two More Phase 3 Ziltivekimab Trials After ZEUS Setback
Novo Nordisk has discontinued the Phase 3 HERMES and ATHENA trials of ziltivekimab after the earlier ZEUS failure raised doubts that IL-6 suppression would translate into cardiovascular benefit. ARTEMIS remains the key ongoing Phase 3 test of the program.
-
Why Lowering IL-6 Wasn’t Enough: What Ziltivekimab’s Cardiovascular Setback Means
Ziltivekimab neutralizes the IL-6 ligand and suppresses downstream inflammatory signaling, but the Phase 3 ZEUS trial showed that strong reductions in free IL-6 and hsCRP did not translate into fewer major cardiovascular events.